Aligos Therapeutics, Inc. Financials
This page shows Aligos Therapeutics, Inc. (ALGS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded drug development dominates here, with tiny revenue and about $80M of annual cash burn defining operations.
Despite a much smaller net loss in FY2025, operating cash flow was still-$82.5M , essentially unchanged from FY2024's-$80.7M ; that means the apparent earnings improvement did not reduce cash needed to run the pipeline. Positive equity was restored by a financing inflow of$101.6M , so the balance sheet improved because new capital arrived, not because operations funded themselves.
With R&D spending of
Year-end cash was only
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Aligos Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Aligos Therapeutics, Inc. scores -11.86, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($41.9M) relative to total liabilities ($35.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Aligos Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Aligos Therapeutics, Inc. generates $3.41 in operating cash flow (-$82.5M OCF vs -$24.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Aligos Therapeutics, Inc. earns $-40.0 in operating income for every $1 of interest expense (-$88.0M vs $2.2M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Aligos Therapeutics, Inc. generated $2.2M in revenue in fiscal year 2025. This represents a decrease of 39.5% from the prior year.
Aligos Therapeutics, Inc.'s EBITDA was -$87.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1.2% from the prior year.
Aligos Therapeutics, Inc. reported -$24.2M in net income in fiscal year 2025. This represents an increase of 81.6% from the prior year.
Aligos Therapeutics, Inc. earned $-2.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 88.3% from the prior year.
Cash & Balance Sheet
Aligos Therapeutics, Inc. held $18.3M in cash against $0 in long-term debt as of fiscal year 2025.
Aligos Therapeutics, Inc. had 6M shares outstanding in fiscal year 2025. This represents an increase of 59.9% from the prior year.
Margins & Returns
Aligos Therapeutics, Inc.'s operating margin was -4024.9% in fiscal year 2025, reflecting core business profitability. This is down 1556.0 percentage points from the prior year.
Aligos Therapeutics, Inc.'s net profit margin was -1106.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 2526.9 percentage points from the prior year.
Aligos Therapeutics, Inc.'s ROE was -45.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Capital Allocation
Aligos Therapeutics, Inc. invested $69.5M in research and development in fiscal year 2025. This represents a decrease of 1.2% from the prior year.
ALGS Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M+1574.6% | $169K-77.2% | $741K-23.2% | $965K+210.3% | $311K-48.7% | $606K-51.5% | $1.3M+17.8% | $1.1M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $23.4M+37.1% | $17.0M-28.8% | $23.9M+71.3% | $14.0M-3.6% | $14.5M-9.5% | $16.0M-4.4% | $16.8M-20.5% | $21.1M |
| SG&A Expenses | $6.4M+29.6% | $4.9M-4.3% | $5.2M-7.0% | $5.6M+10.0% | $5.1M-2.1% | $5.2M+11.6% | $4.6M-27.4% | $6.4M |
| Operating Income | -$26.9M-23.4% | -$21.8M+23.1% | -$28.4M-52.7% | -$18.6M+3.5% | -$19.2M+6.4% | -$20.6M-2.1% | -$20.1M+23.8% | -$26.4M |
| Interest Expense | $100K-83.3% | $600K+50.0% | $400K0.0% | $400K-50.0% | $800K+166.7% | $300K-40.0% | $500K+66.7% | $300K |
| Income Tax | $317K+956.7% | $30K-46.4% | $56K-69.7% | $185K+330.2% | $43K+59.3% | $27K-70.3% | $91K-51.9% | $189K |
| Net Income | -$23.0M-15.9% | -$19.9M+37.0% | -$31.5M-98.8% | -$15.9M-136.8% | $43.1M+152.5% | -$82.2M-326.6% | -$19.3M-480.5% | $5.1M |
| EPS (Diluted) | $-2.21 | N/A | $-3.04-98.7% | $-1.53+27.5% | $-2.11 | N/A | $-3.07 | $0.81 |
ALGS Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $64.6M-27.1% | $88.5M-19.3% | $109.8M-18.5% | $134.7M-10.6% | $150.7M+115.0% | $70.1M-20.7% | $88.4M-18.7% | $108.8M |
| Current Assets | $59.6M-28.0% | $82.9M-19.9% | $103.4M-19.2% | $127.9M-10.7% | $143.2M+130.5% | $62.1M-22.2% | $79.8M-19.8% | $99.6M |
| Cash & Equivalents | $30.0M+63.8% | $18.3M-56.4% | $41.9M+124.8% | $18.7M-74.7% | $73.8M+99.4% | $37.0M+4.7% | $35.3M-21.6% | $45.1M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $32.8M-6.3% | $35.0M-7.8% | $37.9M+15.5% | $32.8M-4.1% | $34.3M-65.4% | $99.1M+158.5% | $38.3M-7.8% | $41.6M |
| Current Liabilities | $23.3M+9.8% | $21.2M-3.4% | $22.0M+8.5% | $20.3M+7.0% | $18.9M-12.8% | $21.7M+3.7% | $21.0M-11.1% | $23.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $31.8M-40.6% | $53.5M-25.5% | $71.8M-29.5% | $101.9M-12.5% | $116.4M+501.9% | -$29.0M-157.8% | $50.1M-25.5% | $67.2M |
| Retained Earnings | -$665.2M-3.6% | -$642.2M-3.2% | -$622.3M-5.3% | -$590.8M-2.8% | -$574.9M+7.0% | -$618.0M-15.3% | -$535.9M-3.7% | -$516.6M |
ALGS Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$23.1M-6.4% | -$21.7M+10.7% | -$24.3M-57.0% | -$15.5M+25.9% | -$20.9M-13.6% | -$18.4M+8.4% | -$20.1M-3.1% | -$19.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $34.9M+1828.4% | -$2.0M-104.2% | $47.7M+221.0% | -$39.4M+10.5% | -$44.1M-320.6% | $20.0M+92.1% | $10.4M-74.0% | $40.0M |
| Financing Cash Flow | -$62K-150.4% | $123K+332.1% | -$53K+70.1% | -$177K-100.2% | $101.7M+104788.7% | $97K+2525.0% | -$4K-101.4% | $281K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ALGS Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -951.5%+11956.1pp | -12907.7%-9080.3pp | -3827.4%-1903.4pp | -1924.0%+4263.4pp | -6187.5%-2794.2pp | -3393.2%-1782.7pp | -1610.5%+879.1pp | -2489.5% |
| Net Margin | -814.1%+10949.8pp | -11763.9%-7507.9pp | -4256.0%-2612.2pp | -1643.8%-15498.5pp | 13854.7%+27410.8pp | -13556.1%-12015.4pp | -1540.7%-2017.7pp | 477.0% |
| Return on Equity | -72.5%-35.4pp | -37.1%+6.8pp | -43.9%-28.3pp | -15.6%-52.6pp | 37.0% | N/A | -38.4%-46.0pp | 7.5% |
| Return on Assets | -35.7%-13.2pp | -22.5%+6.3pp | -28.7%-16.9pp | -11.8%-40.4pp | 28.6%+145.8pp | -117.2%-95.4pp | -21.8%-26.4pp | 4.7% |
| Current Ratio | 2.56-1.3 | 3.90-0.8 | 4.70-1.6 | 6.31-1.2 | 7.56+4.7 | 2.86-1.0 | 3.81-0.4 | 4.23 |
| Debt-to-Equity | 1.03+0.4 | 0.65+0.1 | 0.53+0.2 | 0.32+0.0 | 0.29+3.7 | -3.42-4.2 | 0.77+0.1 | 0.62 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Aligos Therapeutics, Inc.'s annual revenue?
Aligos Therapeutics, Inc. (ALGS) reported $2.2M in total revenue for fiscal year 2025. This represents a -39.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Aligos Therapeutics, Inc.'s revenue growing?
Aligos Therapeutics, Inc. (ALGS) revenue declined by 39.5% year-over-year, from $3.6M to $2.2M in fiscal year 2025.
Is Aligos Therapeutics, Inc. profitable?
No, Aligos Therapeutics, Inc. (ALGS) reported a net income of -$24.2M in fiscal year 2025, with a net profit margin of -1106.7%.
What is Aligos Therapeutics, Inc.'s EBITDA?
Aligos Therapeutics, Inc. (ALGS) had EBITDA of -$87.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Aligos Therapeutics, Inc.'s operating margin?
Aligos Therapeutics, Inc. (ALGS) had an operating margin of -4024.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Aligos Therapeutics, Inc.'s net profit margin?
Aligos Therapeutics, Inc. (ALGS) had a net profit margin of -1106.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Aligos Therapeutics, Inc.'s return on equity (ROE)?
Aligos Therapeutics, Inc. (ALGS) has a return on equity of -45.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Aligos Therapeutics, Inc.'s operating cash flow?
Aligos Therapeutics, Inc. (ALGS) generated -$82.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Aligos Therapeutics, Inc.'s total assets?
Aligos Therapeutics, Inc. (ALGS) had $88.5M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Aligos Therapeutics, Inc. spend on research and development?
Aligos Therapeutics, Inc. (ALGS) invested $69.5M in research and development during fiscal year 2025.
What is Aligos Therapeutics, Inc.'s current ratio?
Aligos Therapeutics, Inc. (ALGS) had a current ratio of 3.90 as of fiscal year 2025, which is generally considered healthy.
What is Aligos Therapeutics, Inc.'s debt-to-equity ratio?
Aligos Therapeutics, Inc. (ALGS) had a debt-to-equity ratio of 0.65 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Aligos Therapeutics, Inc.'s return on assets (ROA)?
Aligos Therapeutics, Inc. (ALGS) had a return on assets of -27.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Aligos Therapeutics, Inc.'s cash runway?
Based on fiscal year 2025 data, Aligos Therapeutics, Inc. (ALGS) had $18.3M in cash against an annual operating cash burn of $82.5M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Aligos Therapeutics, Inc.'s Altman Z-Score?
Aligos Therapeutics, Inc. (ALGS) has an Altman Z-Score of -11.86, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Aligos Therapeutics, Inc.'s Piotroski F-Score?
Aligos Therapeutics, Inc. (ALGS) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Aligos Therapeutics, Inc.'s earnings high quality?
Aligos Therapeutics, Inc. (ALGS) has an earnings quality ratio of 3.41x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Aligos Therapeutics, Inc. cover its interest payments?
Aligos Therapeutics, Inc. (ALGS) has an interest coverage ratio of -40.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Aligos Therapeutics, Inc.?
Aligos Therapeutics, Inc. (ALGS) scores 41 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.